LegalJun 3, 2026, 08:02 AM
Corcept: DOJ Declines Intervention in Qui Tam Lawsuit
AI Summary
Corcept Therapeutics announced that the U.S. Department of Justice, along with the California Department of Insurance and named Plaintiff States, declined to intervene in a civil qui tam action. The lawsuit, initiated in 2017 by a former employee, involved a 2021 DOJ subpoena concerning the sale and promotion of Korlym®. Despite the DOJ's decision, the Relator served an amended complaint on June 2, 2026, and Corcept intends to vigorously defend against all claims.
Key Highlights
- US Department of Justice (DOJ) declined to intervene in a civil qui tam action against Corcept Therapeutics.
- The California Department of Insurance and named Plaintiff States also declined to intervene in the lawsuit.
- The action was initiated in February 2017 by a former employee (Relator).
- DOJ previously issued a records subpoena in November 2021 regarding Korlym® sales and promotion.
- The Relator served Corcept with an amended complaint on June 2, 2026.
- Corcept Therapeutics intends to vigorously defend against all of the Relator's claims.
Price Impact
More from CORT